CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
You may also be interested in...
U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine
PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria
U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine
PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria
Australia's CSL Withdraws Seasonal Trivalent Flu Vaccine For Children Under 5
PERTH, Australia - Australia's CSL Biotherapies has ceased distribution of its pediatric seasonal influenza vaccine following a significant increase in reports of fever and febrile convulsions in children under 5 years of age shortly after receiving CSL's Fluvax Junior vaccine compared to previous seasons, CSL announced June 1